TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32106837
Drug: Prophylactic quadrivalent
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic quadrivalent HPV vaccine
Study: 32758677
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg nebulized fentanyl
Study: 34040400
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 mg twice daily)
Study: 33797074
Drug: Chlorpromazine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 12.5 mg
Study: 33797074
Drug: Prochlorperazine 12.5
Normalized name: prochlorperazine 12.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 12.5 mg
Study: 35506164
Drug: MK-1654 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (100 mg i.m.)
Study: 35506164
Drug: MK-1654 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (300 mg i.m.)
Study: 35506164
Drug: MK-1654 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (300 mg i.v.)
Study: 35506164
Drug: MK-1654 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (1000 mg i.v.)
Study: 33909354
Drug: Acupuncture for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture for regulating shen and strengthening spleen, applied to acupoints Baihui (GV 20), Yintang (GV 29), Tianshu (ST 25), Shangjuxu (ST 37), and Zusanli (ST 36), treatment given once every 2 days, 3 times a week for 6 weeks.
Study: 33909354
Drug: Pinaverium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide, 50 mg orally, 3 times daily for 6 weeks.
Study: 34346566
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine group
Study: 35773693
Drug: Xing‐Nao Kai‐Qiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xing‐Nao Kai‐Qiao acupuncture therapy plus language training
Study: 35773693
Drug: Sham‐acupoint acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham‐acupoint acupuncture therapy plus language training
Study: 33571957
Drug: CAF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (5 mg·kg‐1 caffeine)
Study: 32996442
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First (HF) program with Assertive Community Treatment team support
Study: 32761191
Drug: Low Glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Glycemic Index Therapy Diet (LGIT)
Study: 32761191
Drug: Ketogenic Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic Diet (KD) vs Low Glycemic Index Therapy Diet (LGIT)
Study: 35059305
Drug: Chatbot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chatbot therapy (n = 41)
Study: 34008856
Drug: Astragalus polysaccharide
Normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus polysaccharide (APS) at concentrations of 40, 100, or 400 μg/mL
Study: 34008856
Drug: FA-treated cells
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA-treated cells (FA group, 120 μmol/L)
Study: 33050833
Drug: Naltrexone (mu-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (mu-opioid blocker)
Study: 32032997
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (52 mL/day)
Study: 34814232
Drug: Black myrobalan
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black myrobalan (500 mg capsules, six capsules per day for 4 weeks)
Study: 32940679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the treadmill and electrical neuromuscular stimulation for 15 to 20 minutes each session
Study: 37702442
Drug: Continuous antibiotic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antibiotic prophylaxis
Study: 33289598
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not receiving continuous antibiotic prophylaxis as per model recommendation)
Study: 34083231
Drug: Once‐every‐3‐weeks cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐every‐3‐weeks cisplatin at 100 mg/m2 for two cycles
Study: 34083231
Drug: Once‐a‐week cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐a‐week cisplatin at 40 mg/m2 for six cycles
Study: 32214299
Drug: Paramedian approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedian approach of lumbar epidural injection (LEI)
Study: 32214299
Drug: Midline approach
Normalized name: amidoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midline approach of lumbar epidural injection (LEI)
Study: 32883724
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention to improve adherence to cardiac rehabilitation (CR) and cardiovascular medications.
Study: 34569334
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 2 g tranexamic acid (TXA) and local use of 1 g intraoperatively (Group B)
Study: 34569334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 g tranexamic acid (TXA) and 10 mg rivaroxaban qd treatment postoperatively (Group C)
Study: 34569334
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution intravenously (Group A)
Study: 34380473
Drug: Piezo-surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piezo-surgery with 8 mg dexamethasone
Study: 35803172
Drug: Dual bronchodilator
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual bronchodilator therapy with umeclidinium bromide (UMEC)/vilanterol (VI)
Study: 35803172
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with umeclidinium bromide (UMEC)
Study: 35803172
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with salmeterol (SAL)
Study: 34489263
Drug: Shorter, more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter, more tolerable regimens of oral drugs
Study: 32348699
Drug: short-term existential
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term existential behavioural therapy (sEBT); 2 individual 1-h sessions
Study: 34775948
Drug: Modified high-flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified high-flow nasal cannula (HFNC) oxygen therapy
Study: 32034697
Drug: Plasma endostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma endostatin levels (≥ 84.22 ng/mL)
Study: 32955200
Drug: AXA1665 14.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1665 14.7 g t.i.d.
Study: 36369133
Drug: Electroacupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture and intradermal press needles (Acupuncture group, n=35)
Study: 34670131
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone injection (XR-NTX), n = 283
Study: 35225510
Drug: Intravitreal antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal antifungal agents and systemic therapy
Study: 35225510
Drug: Antifungal stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal stewardship
Study: 32460239
Drug: Chocolate-flavored dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate-flavored dairy milk recovery beverage (1.2 g/kg body mass carbohydrate and 0.4 g/kg body mass protein)
Study: 38652999
Drug: Cenobamate 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 400 mg/day
Study: 35168142
Drug: Cenobamate 200
Normalized name: cenobamate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 200 mg/day and 400 mg/day with SCBs
Study: 33788024
Drug: High-dose purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose purified EPA (icosapent ethyl)
Study: 33788024
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (statins)
Study: 33734167
Drug: HP-3070 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 3.8 mg/24 hours
Study: 33734167
Drug: HP-3070 7.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 7.6 mg/24 hours
Study: 33734167
Drug: HP-3070 (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 (daily application)
Study: 32530717
Drug: Yoga-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-based physical therapy (YPT)
Study: 32989470
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous injection) plus calcitriol (0.5 μg/day) and calcium carbonate (1000 mg/day)
Study: 32989470
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcitriol 0.5 μg/day and calcium carbonate 1000 mg/day without ZOL)
Study: 35642923
Drug: Parenteral vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vitamin B12 (1000 µg IM for initial dose, followed by 3 doses on alternate days for <10 years or 5 doses for >10 years, then monthly 1000 µg IM)
Study: 35642923
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 (1500 µg daily for 3 months, 500 µg for <2 years)
Study: 36364801
Drug: WPH (ERD
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPH (ERD + 20 g/d WPH)
Study: 36364801
Drug: WP (ERD
Approvals — FDA: no, EMA: no, PMDA: no
Description: WP (ERD + 20 g/d WP)
Study: 32761372
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once a day (GA100)
Study: 32761372
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg once a day (GA160)
Study: 32761372
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg twice a day (G2A100)
Study: 32984232
Drug: Immersive aging
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive aging simulation suit and medication review polypharmacy workshop
Study: 32984232
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review polypharmacy workshop (control)
Study: 32646482
Drug: myo-inositol and
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily)
Study: 32646482
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: folic acid alone (400 mcg folic acid daily)
Study: 32450344
Drug: Tirofiban (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (25 μg/Kg as bolus infusion, followed by 0.15 μg/Kg/min continuous infusion for 48 hours), acetylsalicylic acid (250 mg infusion and 75 mg daily for 30 days), clopidogrel (300 mg oral and 75 mg daily for 30 days), fondaparinux (2.5 mg/day subcutaneous for duration of hospital stay)
Study: 32450344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving prophylactic or therapeutic dose heparin
Study: 32398324
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily and durvalumab 1,500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: 33862350
Drug: 5% pomegranate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% pomegranate peel extract solution used with a pulsating jet irrigator
Study: 36431314
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (TG)
Study: 35206569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CFS) maintained their daily routines as normal
Study: 33563509
Drug: Conservative rehabilitation
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative rehabilitation therapy only (control group)
Study: 34429197
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of rosuvastatin 2.5 mg and ezetimibe 10 mg (R2.5+E10)
Study: 34429197
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg monotherapy (E10)
Study: 34429197
Drug: Rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 2.5 mg (R2.5)
Study: 34429197
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg monotherapy (R5)
Study: 32410652
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenge (OFC)
Study: 32130661
Drug: Basal insulin-based
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin-based treatment (insulin glargine plus OADs)
Study: 32130661
Drug: Twice-daily premixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily premixed insulin (NovoLog® Mix 70/30)
Study: 35505122
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) 2.4 g
Study: 32686262
Drug: Autologous skin
Normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skin cell suspension (ASCS) in combination with standard therapy
Study: 33783059
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation (CR) plus Treatment as Usual (TAU)
Study: 33902655
Drug: Online questionnaire
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online questionnaire administration
Study: 616952074
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of paracetamol 1000mg
Study: 616952074
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of paracetamol 1000mg
Study: 33969764
Drug: Paravertebral intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral intramuscular Ozone injection
Study: 33969764
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroid-hyaluronidase injection
Study: 34970741
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the leg region
Study: 34970741
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the abdominal region
Study: 34970741
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the arm region
Study: 34970741
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the abdominal and arm regions
Study: 33518395
Drug: Inpatient single-agent
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient single-agent regimen (Group A): cefazolin sodium 1g preoperatively and every eight hours for 48 hours postoperatively
Study: 33518395
Drug: Extended dual-agent
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dual-agent regimen (Group B): cefazolin sodium 1g preoperatively and every eight hours for 48 hours postoperatively, followed by oral amoxicillin for three days
Study: 36259684
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (weeks 6-16)
Study: 33588408
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) or other interventions for sleep apnea (exact dosage and duration not specified)
Study: 33118908
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) delivered by trained lay health workers; 8 sessions
Study: 34052065
Drug: 20 µg recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg recombinant hepatitis B vaccine (IM20 group)
Study: 34052065
Drug: 60 µg recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg recombinant hepatitis B vaccine (IM60 group)
Study: 35964661
Drug: Delivery room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery room insertion of etonogestrel implant (0 to 2 hours postdelivery)
Study: 35964661
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of etonogestrel implant (24 to 48 hours postdelivery)
Study: 35964661
Drug: Delivery room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery room insertion of etonogestrel implant
Study: 35964661
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of etonogestrel implant
Study: 33544985
Drug: Conventional (chemical)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (chemical) treatment of 40% H2O2
Study: 34387114
Drug: Olanzapine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (low doses)
Study: 34387114
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg or equivalent)
Study: 33081828
Drug: Tocilizumab (1-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (1-h intravenous infusion)
Study: 35364216
Drug: CTP-543 4
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 4 mg twice daily
Study: 35364216
Drug: CTP-543 8
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 8 mg twice daily
Study: 35364216
Drug: CTP-543 12
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 12 mg twice daily
Study: 35010938
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical nutrition therapy (MNT) plus metformin (850 mg twice/day)
Study: 35010938
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical nutrition therapy (MNT) without metformin
Study: 33186771
Drug: Uterine Toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine Toxin Botulinic injections (BTX) under hysteroscopy (200 IU of Incobotulinum-toxin A)
Study: 33186771
Drug: Uterine Toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine Toxin Botulinic injections (BTX) under hysteroscopy
Study: 32379668
Drug: Benson relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson relaxation technique (BRT), performed twice daily for 20 min over one month
Study: 35034428
Drug: Insulin-GLP-1 RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-GLP-1 RA relay group (mean 16.8 ± 11.4 IU/day for 12 weeks, then liraglutide for 12 weeks)
Study: 35034428
Drug: GLP-1 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLP-1 RA first group (liraglutide 0.9 mg for 24 weeks)
Study: 35820444
Drug: Accelerated systemic
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated systemic fibrinolytic therapy (FT) with 100 mg t-PA in 2 hours
Study: 35820444
Drug: Full-dose systemic
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose systemic fibrinolysis
Study: 33136819
Drug: Peer change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer change agent Type I network intervention with opinion leader workshop and telephonic booster sessions
Study: 33136819
Drug: Peer change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer change agent Type I network intervention
Study: 36164334
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline nasal spray)
Study: 34242256
Drug: General health
Normalized name: Walgreens Men-General Health Multivitamin Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: General health messages daily for two months
Study: 34114691
Drug: AUC-targeted therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC-targeted therapeutic drug monitoring (TDM)
Study: 34569167
Drug: Risedronate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (150 mg once monthly)
Study: 32719133
Drug: Experiments involving
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiments involving randomization of policies or treatments
Study: 32719133
Drug: Approval of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approval of policies or treatments